DexTech Medical AB, Interim report July 1, 2023 - March 31, 2024

Summary of the third quarter (2024-01-01 – 2024-03-31)

• Net sales amounted to MSEK 0,0 (0,0)
• Operating profit/loss amounted to MSEK -1,5 (-1,6)
• Earnings per share* SEK -0.08 (-0.08)

Summary of the nine-month period (2023-07-01 – 2024-03-31)

• Net sales amounted to MSEK 0,0 (0,0)
• Operating profit/loss amounted to MSEK -3,9 (-3,7)
• Earnings per share* SEK -0.18 (-0.19)
• Cash and cash equivalents at the end of the period amounted to MSEK 21,1 (27,1)

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.

CEO's comment

The company's Phase 1 study regarding OsteoDex's treatment of multiple myeloma is ongoing and patient recruitment is progressing.

 Principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Ka-rolinska University Hospital, Huddinge. Biomarkers are analysed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. Patients with relapsed/treatment-resistant disease who have received 1-5 prior lines of therapy are included. The primary objective is to confirm safety and tolerability and as a secondary objective to determine possible response to treatment. Documentation of quality of life will also be done (QoL scores).

The first patient was treated in December at Karolinska University Hospital in Huddinge. The first test results from patient 1 were received on January 23 and show a very strong effect on the marker of osteoclast activity (CTX).  The patient has now completed the treatment according to the study proto-col and now has stable disease. Stable disease means that the disease does not progress (slowed down). The result is important and indicates that Osteodex can slow down relapsed/treatment-resistant disease.

An amendment to the study protocol that means that the Company can follow the patient's medical history after completion of treatment has now been approved by the relevant authorities. This pro-vides the Company with information on the duration of OsteoDex's disease-broking effect.

Anders R Holmberg

Contact

Anders Holmberg, CEO, +46 73 324 27 82

Gösta Lundgren, CFO, +46 70 710 47 88

This information is such information that DexTech Medical AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on April 26, 2024 through the care of the above contact persons.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to out-license each drug candidate no later than after completion of the phase II study. DexTech Medical AB is listed on Spotlight Stock Market.